| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
DongKoo Bio & Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩5,940.00 |
| 52 Week High | ₩8,990.00 |
| 52 Week Low | ₩4,615.00 |
| Beta | 0.84 |
| 11 Month Change | -15.14% |
| 3 Month Change | -17.27% |
| 1 Year Change | 12.50% |
| 33 Year Change | -35.85% |
| 5 Year Change | 27.74% |
| Change since IPO | -53.71% |
Recent News & Updates
Shareholder Returns
| A006620 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | 0.3% | 3.2% | 1.9% |
| 1Y | 12.5% | 16.2% | 5.0% |
Return vs Industry: A006620 underperformed the KR Pharmaceuticals industry which returned 13.5% over the past year.
Return vs Market: A006620 exceeded the KR Market which returned 4.4% over the past year.
Price Volatility
| A006620 volatility | |
|---|---|
| A006620 Average Weekly Movement | 10.4% |
| Pharmaceuticals Industry Average Movement | 6.4% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in KR Market | 12.1% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A006620's share price has been volatile over the past 3 months.
Volatility Over Time: A006620's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | 375 | Cho Yong-Jun | www.dongkoo.com |
DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antipyretic anti-inflammatory analgesics, and for the treatment of the respiratory, digestive, genitourinary, and circulatory systems; and quasi-drugs.
DongKoo Bio & Pharma Co., Ltd. Fundamentals Summary
| A006620 fundamental statistics | |
|---|---|
| Market cap | ₩162.17b |
| Earnings (TTM) | ₩14.30b |
| Revenue (TTM) | ₩231.41b |
11.3x
P/E Ratio0.7x
P/S RatioIs A006620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A006620 income statement (TTM) | |
|---|---|
| Revenue | ₩231.41b |
| Cost of Revenue | ₩89.34b |
| Gross Profit | ₩142.07b |
| Other Expenses | ₩127.77b |
| Earnings | ₩14.30b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 523.79 |
| Gross Margin | 61.39% |
| Net Profit Margin | 6.18% |
| Debt/Equity Ratio | 43.6% |
How did A006620 perform over the long term?
See historical performance and comparison